Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.31 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.31 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | HMGCR | P04035 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19480722 | 0.82 | GABRR1 (0.32) | GABRR1CYP1A2 | |
| SCHEMBL18878945 | 0.82 | — | — | |
| SCHEMBL19480718 | 0.82 | — | — | |
| SCHEMBL4585237 | 0.79 | GABRR1 (0.46) | GABRR1CYP1A2FOLH1NAALAD2ENPEP | |
| SCHEMBL4585236 | 0.79 | GABRR1 (0.46) | GABRR1CYP1A2FOLH1NAALAD2ENPEP | |
| SCHEMBL14137394 | 0.79 | — | — | |
| SCHEMBL6452859 | 0.79 | GABRR1 (0.35) | GABRR1CYP1A2FOLH1NAALAD2ENPEP | |
| SCHEMBL28960695 | 0.75 | MEN1 (0.32) | — | |
| SCHEMBL20825944 | 0.74 | ACE2 (0.42) | GABRR1CYP1A2BLM | |
| SCHEMBL5314429 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2682746-B1 | Methods for the diagnosis of ovarian cancer health states and risk of ovarian cancer health states | PHENOMENOME DISCOVERIES INC (CA) | 2017-05-24 | — | — | EP | disclosed |
| US-20160377623-A1 | METHODS FOR THE DIAGNOSIS OF OVARIAN CANCER HEALTH STATES AND RISK OF OVARIAN CANCER HEALTH STATES | MED-LIFE DISCOVERIES LP (CA) | 2016-12-29 | — | — | US | disclosed |
| US-20160305928-A1 | METHODS FOR THE DIAGNOSIS OF OVARIAN CANCER HEALTH STATES AND RISK OF OVARIAN CANCER HEALTH STATES | MED-LIFE DISCOVERIES LP (CA) | 2016-10-20 | — | — | US | disclosed |
| US-20160305928-A1 | METHODS FOR THE DIAGNOSIS OF OVARIAN CANCER HEALTH STATES AND RISK OF OVARIAN CANCER HEALTH STATES | MED-LIFE DISCOVERIES LP (CA) | 2016-10-20 | — | — | US | disclosed |
| US-20100086960-A1 | METHODS FOR THE DIAGNOSIS OF OVARIAN CANCER HEALTH STATES AND RISK OF OVARIAN CANCER HEALTH STATES | PHENOMENOME DISCOVERIES INC. (CA) | 2010-04-08 | — | — | US | disclosed |
| US-20100086960-A1 | METHODS FOR THE DIAGNOSIS OF OVARIAN CANCER HEALTH STATES AND RISK OF OVARIAN CANCER HEALTH STATES | PHENOMENOME DISCOVERIES INC. (CA) | 2010-04-08 | — | — | US | disclosed |
| US-20100062472-A1 | BIOMARKERS FOR DIAGNOSING MULTIPLE SCLEROSIS, AND METHODS THEREOF | PHENOMENOME DISCOVERIES INC. (CA) | 2010-03-11 | — | — | US | disclosed |
| US-20100062472-A1 | BIOMARKERS FOR DIAGNOSING MULTIPLE SCLEROSIS, AND METHODS THEREOF | PHENOMENOME DISCOVERIES INC. (CA) | 2010-03-11 | — | — | US | disclosed |